Figure S2 from Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
crossref（2023）
摘要
FIG S2. Kaplan-Meier plot of OS in the durvalumab monotherapy, durvalumab plus tremelimumab and SoC treatment arms in the NLR ≤ 7 subgroup (A) and NLR > 7 subgroup (B) in EAGLE.
查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要